- Home
- NUVL vs BEP Comparison
NUVL vs BEP Comparison
Compare NUVL & BEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NUVL | BEP |
|---|---|---|
| Founded | 2017 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 8.1B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | NUVL | BEP |
|---|---|---|
| Price | $97.75 | $30.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 10 |
| Target Price | ★ $135.33 | $34.30 |
| AVG Volume (30 Days) | 436.1K | ★ 561.8K |
| Earning Date | 05-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.90% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $14.36 |
| Revenue Next Year | $1,064.25 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $55.54 | $19.29 |
| 52 Week High | $113.02 | $32.78 |
Technical Indicators
Market Signals| Indicator | NUVL | BEP |
|---|---|---|
| Relative Strength Index (RSI) | 42.01 | 45.35 |
| Support Level | $73.22 | $29.25 |
| Resistance Level | $107.13 | $32.75 |
| Average True Range (ATR) | 3.82 | 0.85 |
| MACD | -0.35 | -0.21 |
| Stochastic Oscillator | 19.08 | 29.23 |
Price Performance
Historical ComparisonAbout NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About BEP Brookfield Renewable Partners L.P.
Brookfield Renewable is a globally diversified, multitechnology owner and operator of clean energy assets. The company's portfolio consists of hydroelectric, wind, solar, and storage facilities in North America, South America, Europe, and Asia and totals over 40 gigawatts of installed capacity. Brookfield Renewable invests in assets directly, as well as with institutional partners, joint venture partners, and through other arrangements. The company offers two separate listings for investors: Brookfield Renewable Partners and Brookfield Renewable Corp.